Ali N. Wannas

Ali N. Wannas

Auto-generated profile, based on publicly available information

Ali N. Wannas

Department of Pharmaceutics, Faculty of Pharmacy, University of Kufa, Al-Najaf, Iraq

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2023 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
AWAli N. Wannas
Ali N. Wannas
MAMazin Thamir Abdul-Hasan
Mazin Thamir Abdul-Hasan
KJKrar Kadhim Mohammed Jawad
Krar Kadhim Mohammed Jawad
IRInas F. Abdul Razzaq
Inas F. Abdul Razzaq
Objective: The aim of this study was to formulate, evaluate and characterise nanoemulsion formulation containing a lipophilic drug, Ketoprofen. Methods: Nanoemulsion formulations composed of oil, surfactant, co-surfactants and Ketoprofen were prepared. In all formulations, the percent of surfactants, as well as oil, was varied while the amount of Ketoprofen kept constant. Solubility studies were conducted to select the oil, surfactant and cosurfactant. Phase diagrams were constructed using the aqueous phase titration method. Formulations were selected from the phase diagrams. The prepared nanoemulsions were subjected to different thermodynamic stability tests. Results: Following optimization, the F7 formula (10% oil, 3:1 surfactant to co-surfactant) was thermodynamically stable, with a droplet size of 105 nm and a zeta potential of-26.21 mV. In vitro release study showed that the drug release pattern from formulations F5, F6, F7, F8, F9 and F10 was higher than that of F1, F2, F3 and F4. Conclusion: The present work demonstrates that the nanoemulsion is a promising drug delivery system approach for the enhancement of solubility and dissolution rate of Ketoprofen.

7 January 2022 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
MAMazin Thamir Abdul-Hasan
Mazin Thamir Abdul-Hasan
AAAbulfadhel Jaber Neamah Al-Shaibani
Abulfadhel Jaber Neamah Al-Shaibani
AWAli N. Wannas
Ali N. Wannas
KAKarrar Al-Gburi
Karrar Al-Gburi
Objective: This study was employed to evaluate the quality of marketed oral tablets containing clopidogrel bisulfate. Tablets produced by various companies and commercialized in the Iraq market were used in the study. Methods: Batches of clopidogrel bisulfate conventional tablets (containing 75 mg of drug) were exposed to the quality control tests. These tests involved friability, weight variation, hardness, drug content, disintegration time, and in vitro release study; these tests were conducted depending on USP pharmacopeia. Results: The data indicate that all batches of clopidogrel bisulfate complied with the limitations of USP pharmacopeia for variation of weight, results of the hardness of tablets were 7.2-9.6 Kg/cm2. Friability value (% loss) was less than one, which was within the required limits. The time of disintegration was less than 25 min in both artificial gastric fluid (AGF) and artificial intestinal fluid (AIF). Drug content was observed between 97.1 % and 99.8 %, indicating compliance with the limits of pharmacopeia (85-115 %). An in vitro release study of batches was greater than 80 % within 25 min. Conclusion: All batches of clopidogrel bisulfate were manufactured within the criteria of tablet manufacturing. The quality control tests of tablets showed acceptable pharmaceutical properties (effectiveness and safety) that lie within the limits of USP pharmacopeia.

3 June 2026 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
PDF file
NMNidhal Khazaal Maraie
Nidhal Khazaal Maraie
AWAli N. Wannas
Ali N. Wannas
Doxazosin mesylate is a selective α1-adrenergic receptor antagonist with low oral bioavailability due to poor aqueous solubility and extensive first-pass hepatic metabolism. This study aimed to design and optimize a doxazosin mucoadhesive buccal film to overcome hepatic metabolism and enable rapid drug onset. The buccal films were prepared by solvent casting, using a Plackett–Burman design to screen formulation variables affecting ex vivo mucoadhesive force, followed by a 22 full factorial design to optimize in vitro drug release by varying the concentrations of HPMC, the main film-forming polymer, and glycerin, a plasticizer. The prepared films were characterized for physico-mechanical properties, surface pH, mucoadhesive force, swelling properties, and drug release. In addition, the optimized formula was further characterized by scanning electron microscopy and ex vivo permeation study. The screening study showed that mucoadhesive strength ranged from 28 to 41 g, with the polymer type, polymer concentration, plasticizer type, and plasticizer concentration identified as the most influential variables. The optimized formula (FF3), containing 66 w/w% HPMC K15M and 21 w/w% glycerin, achieved 100% drug release within 15 min with acceptable film properties, in addition, SEM analysis showed a relatively uniform and compact surface with slight undulations, furthermore the ex vivo permeation reached 91% within 15 min, corresponding to a cumulative permeated amount of 1820 µg, a cumulative amount per unit area of 2275 µg/cm2, and an estimated steady-state flux of 12750 µg/cm2/h. It was concluded that the developed buccal film is a promising system for improving doxazosin bioavailability and providing rapid therapeutic onset.

6 June 2023 in Maaen Journal for Medical Sciences
Verified
Journal Article
Open access
PDF file
AWAli Wannas
Ali Wannas
SOSarah K. Obayes
Sarah K. Obayes
ZSZahraa Fathi Sharba
Zahraa Fathi Sharba
RGrana Ghaleb
rana Ghaleb
Lipid nanoparticles (LNP) are the most well-studied first approved nanomedicine for drug delivery of therapeutic and vaccine formulation products. However, their nature is under constant investigation especially their liquid crystal state which leads to their complex biological behavior. LNPs are generally regarded as safe (GRAS) and suitable for ameliorating the toxicity and/or improving the pharmacokinetics of newly approved biomaterials with promising functionality and effects. During the past decade, many promising theranostic applications for LNPs have emerged resulting in huge potential for them in this field. Although there is progress in theranostic application, the gap between the bench and clinical application is undeniable, and that must be addressed to exploit the benefits of these nanomedicines for society.

12 March 2025 in Pharmacia
Verified
Journal Article
Open access
AWAli N. Wannas
Ali N. Wannas
MMMonther F. Mahdi
Monther F. Mahdi
NMNidhal K. Maraie
Nidhal K. Maraie
Hyaluronic acid (HA) is a naturally occurring mucopolysaccharide that interacts specifically with overexpressed receptors on cancer cells, such as CD44, RHAMM, and LYVE-1, enabling targeted drug delivery to tumors. The present work aims to prepare an activated nanolipid carrier (NLC) using HA as a ligand to enhance the selectivity and safety of parenterally administered vinorelbine (Vn). The preparation method included the chemical conjugation of pegylated-DSPE with HA, followed by the loading of Vn using ultrasonication-homogenization to prepare activated HA-NLC (Vn-loaded HA-NLC). In vitro evaluation for the prepared formulation had a mean particle size of 102 nm, a zeta potential of -44.1 mV, and gave a drug release of 85.23% within 48 hours with an IC50 of 35.7 µg/mL against the lung cancer cell line A549 in comparison to the marketed drug and non-activated Vn-loaded NLC, which gave IC50 values of 45.65 µg/mL and 57.29 µg/mL, respectively. The in vivo study in mice of the Kunming strain included the induction of lung cancer (LL2) xenograft (equivalent to humanized A549), measurement of mice body weight and tumor volume, histopathological study for 4 weeks, and MRI follow-up scan of tumor tissue for 24 hours using SPION as a contrast agent. The result showed a significant (P < 0.05) increase in body weight, extensive tumor apoptosis, smaller tumor size, and better accumulation inside tumor tissue for mice treated with activated HA-NLC compared to non-activated NLC and marketed products. It was concluded that HA-NLC promoted the selective targeting and accumulation of Vn inside tumor tissue, prolonging the retention duration and enhancing the drug’s cytotoxic effect with increased mice weight as a sign of safety.